| Infantile Severe Myoclonic Epilepsy
Diacomit vs Fintepla
Side-by-side clinical, coverage, and cost comparison for infantile severe myoclonic epilepsy.Deep comparison between: Diacomit vs Fintepla with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsFintepla has a higher rate of injection site reactions vs Diacomit based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Fintepla but not Diacomit, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Diacomit
Fintepla
At A Glance
Oral
Twice or three times daily
Anticonvulsant
Oral
Twice daily
5-HT2 receptor agonist
Indications
- Infantile Severe Myoclonic Epilepsy
- Infantile Severe Myoclonic Epilepsy
- Lennox-Gastaut syndrome
Dosing
Infantile Severe Myoclonic Epilepsy 50 mg/kg/day orally in 2 or 3 equally divided doses (25 mg/kg twice daily or 16.67 mg/kg three times daily) for patients 6 months of age and older weighing 7 kg or more; maximum 3,000 mg/day.
Infantile Severe Myoclonic Epilepsy, Lennox-Gastaut syndrome Initial 0.1 mg/kg twice daily orally, titrated weekly; maintenance up to 0.35 mg/kg twice daily (max 26 mg/day); with concomitant stiripentol plus clobazam, maximum 0.2 mg/kg twice daily (max 17 mg/day).
Contraindications
—
- Hypersensitivity to fenfluramine or any of the excipients in FINTEPLA
- Concomitant use, or within 14 days of administration, of monoamine oxidase inhibitors
Adverse Reactions
Most common (>=10%) Somnolence, decreased appetite, agitation, ataxia, weight decreased, hypotonia, nausea, tremor, dysarthria, insomnia
Serious Somnolence, decreased appetite and decreased weight, neutropenia and thrombocytopenia, withdrawal symptoms, suicidal behavior and ideation
Most common (>=10%) Decreased appetite, somnolence/sedation/lethargy, diarrhea, fatigue/malaise/asthenia, abnormal echocardiogram, ataxia/balance disorder/gait disturbance, blood pressure increased, drooling/salivary hypersecretion, pyrexia, upper respiratory tract infection, vomiting, weight decreased
Serious Valvular heart disease, pulmonary arterial hypertension, decreased appetite and decreased weight, somnolence/sedation/lethargy, suicidal behavior and ideation, serotonin syndrome, increase in blood pressure, glaucoma, status epilepticus
Postmarketing Aggression
Pharmacology
DIACOMIT is an anticonvulsant whose exact mechanism is unknown; possible mechanisms include direct modulation of the GABA-A receptor and indirect inhibition of cytochrome P450 activity that increases plasma concentrations of clobazam and its active metabolite norclobazam.
Fenfluramine and its metabolite norfenfluramine exhibit agonist activity at serotonin 5-HT2 receptors; the precise mechanism by which this produces antiseizure effects in Dravet syndrome and Lennox-Gastaut syndrome is unknown, though 5-HT2B receptor agonism is associated with valvular heart disease and pulmonary arterial hypertension risk.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Diacomit
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (11/12) · Qty limit (11/12)
Fintepla
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (11/12) · Qty limit (9/12)
UnitedHealthcare
Diacomit
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (6/8) · Qty limit (4/8)
Fintepla
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (4/8) · Qty limit (2/8)
Humana
Diacomit
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (1/3) · Qty limit (3/3)
Fintepla
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableDiacomit Bridge Program
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
$25
ONWARD Copay Assistance Program: FinteplaCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
DiacomitView full Diacomit profile
FinteplaView full Fintepla profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.